Clinical Trials Logo

Clinical Trial Summary

This study explores the potential values of a new blood test approach to detect measurable residual disease or early coming back of cancer (recurrence)/cancer growing, spreading, or getting worse (progression) in patients with liver cancer that can be removed by surgery (resectable). The development of novel cancer biomarkers for liver cancer may help in clinical decision making and lead to improvements in patient outcomes by facilitating prediction of the response to specific treatments, improved monitoring of patients on treatment, and better prognostication of patient outcomes, thus improving stratification for clinical trials.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To isolate plasma deoxyribonucleic acid (DNA) methylation panel from the peripheral blood of treated patients with hepatocellular carcinoma that will correlate with disease progression or measurable residual disease. II. To correlate the mutations/ DNA methylation in peripheral blood with those identified in parallel tumor samples from the same patients with hepatocellular (HCC). OUTLINE: Patients undergo collection of blood samples at 4-6 weeks prior to surgery/ablation and at 12 weeks, 6, 12, 18 and 24 months after surgery/ablation. Patients' previously collected tissue samples are analyzed. Patients' medical records are also reviewed at baseline, 4-6 weeks prior to surgery/ablation, 12 weeks, 6, 12, 18 and 24 months after surgery/ablation, and then every 6 months for 3 years. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04856046
Study type Observational
Source Mayo Clinic
Status Not yet recruiting
Start date May 1, 2021
Completion date May 15, 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2
Not yet recruiting NCT04721132 - Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer Phase 2
Suspended NCT02379377 - 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant Phase 1
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Recruiting NCT04701060 - Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT04857684 - SBRT + Atezolizumab + Bevacizumab in Resectable HCC Early Phase 1
Not yet recruiting NCT04834986 - Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma Phase 2